Valuation: Daxor Corporation

Market Cap 58.38M 50.03M 46.88M 42.82M 80.81M 5.57B 81.61M 553M 215M 2.81B 219M 214M 9.3B P/E 2026 *
-47.6x
P/E 2027 * -333x
Enterprise Value 58.38M 50.03M 46.88M 42.82M 80.81M 5.57B 81.61M 553M 215M 2.81B 219M 214M 9.3B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 2.81x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week-2.82%
Current month-4.76%
1 month-4.31%
6 months-17.49%
Current year-32.20%
1 week 9.76
Extreme 9.76
10.3
1 month 9.76
Extreme 9.76
11.15
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.31%-7.83%+2.83% 58.38M
+0.34%+7.36%+37.24%+137.44% 16.76B
+0.13%+9.86%+75.06%+173.98% 14.35B
+0.41%-0.46%-9.13%+30.35% 9.23B
+0.83%+8.79%+52.08%+160.70% 8.28B
+0.85%+2.11%-20.06%-15.33% 7.08B
+2.34%+8.07%+19.75%+49.30% 7.03B
+0.25%+3.53%+12.66%+31.78% 4.97B
+0.64%+0.55%+11.13%+9.04% 4.11B
-0.33%+0.56% - - 3.95B
Average +0.61%+2.78%+18.99%+64.45% 8.42B
Weighted average by Cap. +0.57%+3.74%+29.96%+95.23%

Financials

2026 *2027 *
Net sales 11.9M 10.2M 9.55M 8.73M 16.47M 1.13B 16.63M 113M 43.88M 572M 44.68M 43.71M 1.9B 20.8M 17.82M 16.7M 15.26M 28.79M 1.98B 29.07M 197M 76.69M 1B 78.1M 76.4M 3.31B
Net income -1.2M -1.03M -964K -880K -1.66M -114M -1.68M -11.37M -4.42M -57.72M -4.51M -4.41M -191M -200K -171K -161K -147K -277K -19.07M -280K -1.89M -737K -9.62M -751K -735K -31.86M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
26-08-25 US$10.00 - 1,082
26-08-24 US$0.000000 -100.00% 279
26-08-21 US$10.00 - 2,017
26-08-20 US$0.000000 -100.00% 27
26-08-19 US$10.30 +0.10% 202
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.00USD
Average target price
22.50USD
Spread / Average Target
+125.00%

Quarterly revenue - Rate of surprise